Semax: The Nootropic Peptide with 30 Years of Clinical Evidence

Semax is a heptapeptide (seven-amino-acid chain) derived from the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10) with an added Pro-Gly-Pro tripeptide tail that stabilises it against enzymatic degradation. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, Semax has been approved as a pharmaceutical nootropic in Russia and several CIS countries since 1994 – giving it one of the longest clinical track records of any nootropic compound.

What distinguishes Semax from most nootropics is its mechanism: rather than modulating a single neurotransmitter system, it upregulates BDNF (brain-derived neurotrophic factor) and other neurotrophins that support the structural health and plasticity of neural networks. The result is genuine cognitive enhancement through neuroplasticity, not stimulation.

The ACTH Connection (and Why Semax Is Different)

ACTH (adrenocorticotropic hormone) is a 39-amino-acid pituitary hormone primarily known for stimulating cortisol release from the adrenal glands. However, the ACTH(4-10) fragment – the seven-amino-acid sequence from which Semax is derived – has no corticotropic (cortisol-stimulating) activity whatsoever. Instead, this fragment has its own distinct set of neuromodulatory effects that were first identified in the 1970s and 1980s by Russian and Dutch researchers.

The critical difference: Semax produces cognitive and neuroprotective benefits without any of the HPA axis stimulation or cortisol elevation associated with full-length ACTH. It does not cause adrenal stimulation, it does not raise cortisol, and it does not produce the stress-like effects of corticotropic hormones.

BDNF: The Key to Semax’s Cognitive Effects

BDNF (brain-derived neurotrophic factor) is arguably the single most important molecule for cognitive function and brain health. It supports survival of existing neurons, encourages growth and differentiation of new neurons (neurogenesis), and strengthens synaptic connections – the physical basis of learning and memory. BDNF levels decline with age, stress, depression, and sedentary lifestyle, correlating with cognitive decline, mood disorders, and neurodegeneration.

Semax is one of the most potent known pharmacological upregulators of BDNF expression. Research has documented increases of 200-800% in BDNF mRNA expression in key brain regions following Semax administration, with the magnitude depending on region and dose:

• Hippocampus: Critical for memory formation and spatial navigation. BDNF upregulation here directly supports learning and memory consolidation
• Prefrontal cortex: Responsible for executive function, working memory, and attention. Enhanced BDNF here improves focus and decision-making capacity
• Basal forebrain: Supports cholinergic neurons that project throughout the cortex, influencing alertness and attentional processing

Beyond BDNF: NGF and GDNF

Semax also upregulates nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF). NGF supports cholinergic neuron health and peripheral nerve function, while GDNF is particularly important for dopaminergic neurons – the same neurons that degenerate in Parkinson’s disease. This multi-neurotrophin profile gives Semax a broader neuroprotective effect than single-neurotrophin-targeting compounds.

Clinical Applications in Russia

Semax has been approved and used clinically in Russia since 1994, providing a substantial body of clinical experience:

Stroke and Cerebrovascular Events

The most extensively studied clinical application. Semax administered during acute ischaemic stroke reduced infarct volume, improved neurological outcome scores, and enhanced functional recovery in multiple clinical trials. The mechanism involves both BDNF-mediated neuroprotection (keeping at-risk neurons alive in the penumbral zone) and anti-inflammatory effects that reduce secondary damage. Semax is included in the Russian national clinical guidelines for acute stroke management.

Cognitive Enhancement in Healthy Individuals

Clinical studies on healthy volunteers showed improved attention, memory encoding, and cognitive processing speed. Unlike stimulant-based nootropics (caffeine, modafinil, amphetamines), the cognitive improvements from Semax do not come with jitteriness, anxiety, insomnia, or crash – because the mechanism is neurotrophin-mediated plasticity rather than neurotransmitter depletion.

Optic Nerve Atrophy

Semax has been approved for the treatment of optic nerve atrophy, where it improved visual function in clinical trials. The optic nerve is essentially a CNS structure, and Semax’s neurotrophic effects appear to support surviving retinal ganglion cells and improve signal transmission along partially damaged nerve fibres.

ADHD and Cognitive Dysfunction

Paediatric studies in Russia have used Semax for ADHD and cognitive development disorders, with improvements in attention, impulsivity, and academic performance. The non-stimulant mechanism is particularly attractive for paediatric applications where the side effects of methylphenidate and amphetamines are concerning.

Neurotransmitter Effects

Beyond neurotrophin upregulation, Semax modulates several neurotransmitter systems:

• Dopamine: Semax modulates dopaminergic signalling, particularly in the striatum and prefrontal cortex. This contributes to improved motivation, focus, and reward processing without the euphoria or dependency risk of direct dopamine agonists
• Serotonin: Modulation of serotonergic transmission contributes to mood stabilisation and may explain the mild anxiolytic effects reported by some users
• Acetylcholine: Through NGF upregulation and support of cholinergic neurons, Semax indirectly enhances cholinergic transmission – the neurotransmitter system most directly linked to attention and memory

Semax vs Selank: Understanding the Difference

Semax and Selank were developed by the same Russian research institute and are sometimes confused. The distinction is important:

• Semax is primarily cognitive – it enhances focus, memory, and neuroplasticity through BDNF upregulation. It is the “performance” peptide
• Selank is primarily anxiolytic – it reduces anxiety and stabilises mood through GABAergic and serotonergic modulation. It is the “calm” peptide

Many researchers combine them for complementary effects: Semax provides the cognitive drive while Selank prevents the anxiety that can accompany intense focus periods. The combination is sometimes called the “Russian nootropic stack.”

Administration and Bioavailability

Semax is typically administered intranasally (nasal drops), which provides rapid absorption across the nasal mucosa and direct access to the CNS via the olfactory pathway. Intranasal bioavailability is high due to the peptide’s small size and the addition of the Pro-Gly-Pro stabilising sequence. Subcutaneous injection is also used in research settings, providing systemic bioavailability with slightly different pharmacokinetics.

Key Takeaways

• Semax is an ACTH(4-10) analogue that enhances cognition through BDNF, NGF, and GDNF upregulation – not stimulation
• It has been approved as a pharmaceutical nootropic in Russia since 1994, with clinical applications in stroke, cognitive enhancement, and optic nerve atrophy
• BDNF increases of 200-800% have been documented in key brain regions (hippocampus, prefrontal cortex)
• Unlike stimulant nootropics, Semax does not cause jitteriness, insomnia, tolerance, or crash
• It has no cortisol-stimulating activity despite its ACTH origin – the active fragment is distinct from the corticotropic region
• Pairs well with Selank (anxiolytic) for combined cognitive enhancement and anxiety reduction